Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.

Hussain Abdulrahman Al-Omar Hind Saleh Almodaimegh Abubker Omaer Lamya M AlzubaidiBandar Al-HarbiIbtisam Al-HarbiMohamed HassanOmar Akhtar

Published in: Journal of medical economics (2024)

CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.

Keyphrases

emergency department
decision making
type diabetes
cardiovascular disease
saudi arabia
cardiovascular risk factors
adverse drug
drug induced